Stock TERN TERNS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Terns Pharmaceuticals, Inc.

Equities

TERN

US8808811074

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
6 USD +2.39% Intraday chart for Terns Pharmaceuticals, Inc. +1.69% -7.55%
May. 13 Terns Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 08 Terns Pharmaceuticals, Inc. Announces Executive Changes CI

Business Summary

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its pipeline includes three clinical-stage development programs: TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity and other metabolic diseases. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic stability and liver distribution. It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.

Number of employees: 66

Managers

Managers TitleAgeSince
Amy Burroughs CEO
 Chief Executive Officer 54 Feb. 06
Erin Quirk PSD
 President 53 18-12-31
Mark Vignola DFI
 Director of Finance/CFO 47 20-08-10
Bryan Yoon COO
 Chief Operating Officer 46 20-10-31
Jeffrey R. Jasper CTO
 Chief Tech/Sci/R&D Officer - 22-01-05
Justin Ng IRC
 Investor Relations Contact - -
Emil T. Kuriakose PRN
 Corporate Officer/Principal 44 23-04-30
Melita Jung PRN
 Corporate Officer/Principal 47 Apr. 21

Members of the board

Members of the board TitleAgeSince
David Fellows CHM
 Chairman 67 20-11-30
Jeffrey Kindler BRD
 Director/Board Member 68 20-11-30
Carl Gordon BRD
 Director/Board Member 59 18-09-30
Hong Bo Lu BRD
 Director/Board Member 53 20-03-31
Radhika Tripuraneni BRD
 Director/Board Member 44 22-07-25
Jill Quigley BRD
 Director/Board Member 49 20-11-30
Amy Burroughs CEO
 Chief Executive Officer 54 Feb. 06
Erin Quirk PSD
 President 53 18-12-31
Ann Taylor BRD
 Director/Board Member 67 21-09-27

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 64,677,145 63,525,621 ( 98.22 %) 0 98.22 %

Shareholders

NameEquities%Valuation
OrbiMed Advisors Private Equity
11.78 %
7,619,135 11.78 % 35 M $
Vivo Capital LLC
9.648 %
6,237,329 9.648 % 29 M $
Deep Track Capital LP
9.435 %
6,100,000 9.435 % 28 M $
Point72 Asset Management LP
6.065 %
3,921,226 6.065 % 18 M $
Millennium Management LLC
5.382 %
3,479,630 5.382 % 16 M $
Millennium Management LLC
5.310 %
3,432,792 5.310 % 16 M $
Venrock Associates
5.275 %
3,410,058 5.275 % 16 M $
BlackRock Advisors LLC
4.800 %
3,103,127 4.800 % 14 M $
Citadel Securities GP LLC
4.587 %
2,965,586 4.587 % 14 M $
LAV Management Co., Ltd.
4.488 %
2,901,566 4.488 % 13 M $

Company contact information

Terns Pharmaceuticals, Inc.

1065 East Hillsdale Boulevard Suite 100

94404, Foster City

+650 525 5535

http://www.ternspharma.com
address Terns Pharmaceuticals, Inc.(TERN)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
6 USD
Average target price
14.21 USD
Spread / Average Target
+136.90%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
TERNS PHARMACEUTICALS, INC. Stock Terns Pharmaceuticals, Inc.
-7.55% 388M
MODERNA, INC. Stock Moderna, Inc.
+67.53% 63.85B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.77% 41.83B
LONZA GROUP AG Stock Lonza Group AG
+45.66% 40.65B
CELLTRION, INC. Stock Celltrion, Inc.
-10.72% 27.12B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.30% 26.52B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.79% 18.69B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+4.70% 12.73B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+24.10% 12.11B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.41% 12.07B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. TERN Stock
  4. Company Terns Pharmaceuticals, Inc.